Evidence map›Paper›PMID 35834155›Full record

ArticleDrug safety2022

A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).

Lorenzo Villa-Zapata, Ainhoa Gómez-Lumbreras, John Horn, Malinda S Tan, Richard D Boyce, Daniel C Malone

Abstract read
PubMed Publisher
In one paragraph

Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Lorenzo Villa-ZapataDepartment of Pharmacy Practice, College of Pharmacy, Mercer University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-3821-4595
Ainhoa Gómez-LumbrerasDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, 30 S 2000 E, Salt Lake City, UT, 84112, USA.ORCID http://orcid.org/0000-0002-3916-0402
John HornDepartment of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4525-4250
Malinda S TanDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, 30 S 2000 E, Salt Lake City, UT, 84112, USA.
Richard D BoyceDepartment of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-2993-2085
Daniel C MaloneDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, 30 S 2000 E, Salt Lake City, UT, 84112, USA. dan.malone@utah.edu.ORCID http://orcid.org/0000-0002-5006-9394
University of Utah · USMercer University Health Sciences Center · USUniversity of Pittsburgh · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTizanidine is primarily metabolized via cytochrome P450 (CYP) 1A2 and therefore medications that inhibit the enzyme will affect the clearance of tizanidine, leading to increased plasma concentrations of tizanidine and potentially serious adverse events.

objectivesOur aim was to study the occurrence of adverse events reported in the FDA Adverse Event Reporting System (FAERS) involving the combination of tizanidine and drugs that inhibit the metabolic activity of CYP1A2.

methodsA disproportionality analysis of FAERS reports from 2004 quarter 1 through 2020 quarter 3 was conducted to calculate the reporting odds ratio (ROR) of reports mentioning tizanidine in a suspect or interacting role or having any role, a CYP1A2 inhibitor, and the following adverse events: hypotension, bradycardia, syncope, shock, cardiorespiratory arrest, and fall or fracture.

resultsA total of 89 reports were identified mentioning tizanidine, at least one CYP1A2 inhibitor, and one of the adverse events of interest. More than half of the reports identified tizanidine as having a suspect or interacting role (n = 59, 66.3%), and the reports more frequently involved women (n = 58, 65.1%). The median age was 56.1 years (standard deviation 17.1). Some of the important safety signals included interactions between tizanidine in a suspect or interacting role and ciprofloxacin (ROR for hypotension 28.1, 95% confidence interval [CI] 19.2-41.2) or fluvoxamine (ROR for hypotension 36.9, 95% CI 13.1-103.4), and also when reported in "any role" with ciprofloxacin (ROR for hypotension 6.3, 95% CI 4.7-8.5), fluvoxamine (ROR for hypotension 11.4, 95% CI 4.5-28.8), and zafirlukast (ROR for falls 16.0, 95% CI 6.1-42.1).

conclusionsReports involving tizanidine and a CYP1A2 inhibitor have higher odds of reporting hypotension. This study suggests that concurrent use of tizanidine with CYP1A2 inhibitors may lead to serious health consequences associated with low blood pressure such as falls and fractures.

Indexed as

Adverse Drug Reaction Reporting SystemsCytochrome P-450 CYP1A2 InhibitorsDrug InteractionsCiprofloxacinClonidineCytochrome P-450 CYP1A2FemaleFluvoxamineHumansHypotensionMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationCiprofloxacinClonidineCYP1A2 protein, humanCytochrome P-450 CYP1A2Cytochrome P-450 CYP1A2 InhibitorsFluvoxaminetizanidine

Identifiers

PMID35834155
OpenAlexW4285390912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.